Back Row (left to right): Dean Hakanson, MD, Chief Medical Officer; Iris Tam, PharmD, Vice President, Patient Access & Quality; Barbara Finn, Vice President of Regulatory & Quality Assurance; Alan Foster, PhD, Vice President, Research; Eric Loumeau, General Counsel & Chief Compliance Officer; Bob Savel, Chief Technical Officer; Liza Wallace, Vice President, Clinical Operations; David Weber, PhD, President & Chief Executive Officer; Julie Burgess, Vice President, Finance & Administration; Tony Yost, Chief Commercial Officer; Rye Dalton, Vice President, Commercial Operations; Front Row (left to right): Carl LeBel, PhD, Chief Scientific Officer; Dina Lynch, Vice President, Market Access; Paul Cayer, Chief Financial & Business Officer; Carol Baum, Vice President, Marketing; Not Pictured: Fabrice Piu, PhD, Vice President, Pre-Clinical Development

Executive Team

David Weber

David A. Weber, Ph.D.

Chief Executive Officer, President and Board Member

David A. Weber, Ph.D. has served as our President and Chief Executive Officer and on our board of directors since November 2010. Prior to joining us, Dr. Weber served from February 2004 to April 2010 as the Chief Executive Officer of MacuSight, Inc., a developer of a sustained delivery formulation of sirolimus for the treatment of severe ophthalmic diseases. Prior to MacuSight, Dr. Weber served as acting Chief Executive Officer and Executive Vice President of Oculex Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of intraocular pharmaceuticals and drug delivery systems, until its acquisition by Allergan in 2003. Dr. Weber has also held management positions with Oral-B Laboratories, a developer and manufacturer of oral hygiene products, and with Procter & Gamble, Co., a consumer products company. Dr. Weber received his Ph.D. in medical microbiology from Creighton University and his Master’s and Bachelor’s degrees in biological sciences from Wichita State University.

Paul Cayer

Paul E. Cayer

Chief Financial & Business Officer

Paul E. Cayer has served as our Chief Business Officer since October 2008 and Chief Financial Officer since October 2010. Mr. Cayer brings more than 25 years of experience in the pharmaceutical, medical device and healthcare technology field. Prior to joining our company, Mr. Cayer served from 2005 to 2008 as Senior Vice President, Corporate Development for Verus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of allergic and respiratory disorders in children. From 2001 to 2005, Mr. Cayer served as the Chief Financial Officer and Senior Vice President, Business Development of Targeted Molecules Corporation, a biopharmaceutical company. Mr. Cayer has also held various management positions with Gensia Pharmaceuticals, Inc., a biopharmaceutical company, Acuson, a provider of medical ultrasound systems, Castle & Cooke, a consumer products company, and served as consultant with Booz-Allen & Hamilton, a management and technology consulting firm. Mr. Cayer received his MBA and Bachelor’s degree in biomechanical engineering from Harvard University.

Car LeBel

Carl LeBel, Ph.D.

Chief Scientific Officer

Carl LeBel, Ph.D. has served as our Chief Scientific Officer since April 2009. Dr. LeBel has more than 25 years of pharmaceutical research and development experience. From 2003 to 2007, Dr. LeBel served as Executive Director and in a variety of other positions from 1993 to 2003 at Amgen, Inc., biopharmaceutical company. From 1991 to 1993, Dr. LeBel served as Research Scientist at Alkermes, Inc., a biopharmaceutical company. From 1990 to 1991, Dr. LeBel served as Consultant at Arthur D. Little, Inc., a management and technology consulting firm. He is also a scientific fellow of the American Academy of Otolaryngology—Head & Neck Surgery, a full member of the Association for Research in Otolaryngology, and a full member of both the American Association for the Advancement of Science and the Society of Toxicology. Dr. LeBel received his Bachelor’s degree in chemistry from the University of Detroit and a Ph.D. in Biomedical Sciences/Toxicology from Northeastern University.

Robert Savel

Robert Michael Savel, II

Chief Technical Officer

Robert Michael Savel, II has served as our Chief Technical Officer since January 2014. From September 2011 to December 2013, Mr. Savel served as General Manager and Senior Vice President of Operations for Optimer Pharmaceuticals, Inc., a biopharmaceuticals company. From September 2010 to June 2011, Mr. Savel served as Senior Vice President and Chief Technical Officer for Inspire Pharmaceuticals, Inc., an ophthalmic pharmaceutical company. From April 2008 to September 2010, Mr. Savel served as President of Savel Enterprises LLC, a management consulting firm. From April 2007 to April 2008, Mr. Savel served as the Senior Vice President of Technical Operations for PDL BioPharma, an antibody manufacturer. Earlier in his career, he held leadership operating positions with Johnson & Johnson, a medical devices, pharmaceutical and consumer packaged goods manufacturer, which included the position of Vice President, Quality and Compliance. Mr. Savel received his Bachelor’s degree in mechanical engineering from Virginia Polytechnic Institute and State University in Blacksburg, Virginia.

Tony Yost

Anthony J. Yost

Chief Commercial Officer

Anthony J. Yost has served as our Chief Commercial Officer since October 2014. From January 2012 to May 2014, Mr. Yost served as Chief Commercial Officer for Prometheus, Inc., a specialty pharmaceutical and diagnostic company. From August 2011 to January 2012, Mr. Yost served as Chief Commercial Officer for EKR Therapeutics, Inc., a specialty pharmaceutical company. From October 2010 to April 2011, he was the head of Sales and Marketing at PacificCord, a stem cell storage biotechnology company. From October 2008 to June 2010, Mr. Yost served as General Manager for the Western U.S. Operating Unit of Novartis AG, a pharmaceutical company. From November 2003 to September 2008, Mr. Yost served as President for Innovex North America, a pharmaceutical sales and marketing services division of Quintiles Transnational Corporation. From February 1998 to November 2003, he held various positions at Schering-Plough Corporation, a pharmaceutical manufacturing company, which included Vice President in the Acute Coronary Syndromes Business Unit, General Manager of Commercial and Manufacturing Operations in Portugal, Vice President of Managed Care and Vice President of the Cardiovascular Business Unit. Earlier in his career he worked for Boehringer Mannheim and Eli Lilly and Company. He is also currently a member of the board of directors of InSite Vision, Inc., a public company. Mr. Yost received his Bachelor’s degree in pharmacy from Purdue University.

Dean Hakanson

Dean Hakanson, M.D.

Chief Medical Officer

Dean Hakanson, M.D. has served as our Chief Medical Officer since April 2015. From May 2010 to March 2015, Dr. Hakanson served as Vice President and Head of Health Economics and Outcomes Research for U.S. Medical and Regulatory Affairs, and from July 2009 to May 2010 as Vice President and Medical Head of the Western U.S. Operating Unit, for Novartis AG, a pharmaceutical company. From January 2008 to July 2009, Dr. Hakanson served as Vice President of Healthcare Access for Bristol-Myers Squibb Company, a manufacturer of prescription pharmaceuticals. From June 2005 to January 2008, Dr. Hakanson served as Head of Value-Based Health Care/Payer Field Team for Genentech, Inc., a biotechnology corporation which is now a division of F. Hoffman-La Roche AG. From 1998 to 2005, he held various positions at GlaxoSmithKline plc, a pharmaceutical and consumer healthcare company, which included Vice President, Medical Affairs Commercial Operations and Vice President of Managed Markets, National Accounts. Earlier in his career he practiced clinical medicine in critical care at John C. Lincoln IDS and Tenet Healthcare Corporation. He is also a Fellow with the American Academy of Otolaryngology – Head and Neck Surgery and a Diplomat of the American Board of Anesthesiology, American Medical Association and the American Association for Physician Leadership. Currently he has an active license to practice medicine in California and Arizona. Dr. Hakanson received his Bachelor’s degree in cellular physiology and physics from the University of Denver, a Medical degree from the University of Colorado School of Medicine, anesthesiology residency training at the University of Michigan and training in critical care at the University of California, Davis Medical Center.

Eric Loumeau

Eric Loumeau

General Counsel and Chief Compliance Officer

Eric Loumeau has served as our General Counsel and Chief Compliance Officer since May 2015 and Secretary since July 2015. Mr. Loumeau brings over 23 years of experience as in-house legal counsel and compliance officer for several biopharmaceutical companies and as outside corporate counsel supporting healthcare and technology based client companies. Prior to joining our company, Mr. Loumeau was the Vice President of Legal Affairs at The Medicines Company from December 2013 to May 2015, a role he held following the company's acquisition of Rempex Pharmaceuticals. From June 2011 to December 2013 Mr. Loumeau served as Vice President, Chief Financial Officer and Chief Compliance Officer of Rempex Pharmaceuticals. From January 2009 to January 2011 he was Partner at Bass, Berry & Sims, PLC, and from May 2007 to January 2009 he was Partner at Mintz Levin Cohn Ferris Glovsky and Popeo PC. From October 1999 to May 2007, Mr. Loumeau served as General Counsel and Chief Compliance Officer for Hollis-Eden Pharmaceuticals, a publicly traded biotechnology company. Prior to this role he was Partner and Associate at Cooley LLP from April 1995 to October 1999, and an Associate at Skadden, Arps, Slate, Meagher & Flom LLP, from September 1991 to April 1995. Mr. Loumeau obtained a Juris doctorate from Boalt Hall School of Law at the University of California, Berkeley, including spending his final year at Harvard Law School through the Harvard-Boalt Exchange Program. He obtained a Bachelor's degree in finance from Brigham Young University.